These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 19212639

  • 41. [Safety and efficacy of weekly paclitaxel followed by FEC100 as primary systemic therapy for breast cancer].
    Naito K, Oura S, Yoshimasu T, Tamaki T, Ohta F, Nakamura R, Shimizu Y, Kiyoi M, Hirai Y, Miyasaka M, Okamura Y.
    Gan To Kagaku Ryoho; 2009 Feb; 36(2):251-4. PubMed ID: 19223740
    [Abstract] [Full Text] [Related]

  • 42. Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group.
    Koutras AK, Fountzilas G, Dafni U, Dimopoulos MA, Pectasides D, Klouvas G, Papakostas P, Kosmidis P, Samantas E, Gogas H, Briasoulis E, Vourli G, Petsas T, Xiros N, Kalofonos HP, Hellenic Cooperative Oncology Group.
    Anticancer Res; 2008 Feb; 28(5B):2913-20. PubMed ID: 19031934
    [Abstract] [Full Text] [Related]

  • 43. Effect of epoetin on survival in patients with breast cancer.
    Codacci-Pisanelli G, Spinelli GP, Tomao S.
    J Clin Oncol; 2008 May 20; 26(15):2599; author reply 2599-600. PubMed ID: 18487580
    [No Abstract] [Full Text] [Related]

  • 44. Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment.
    Corapcioglu F, Aksu G, Basar EZ, Demirel A, Oncel S, Mutlu A.
    Pediatr Hematol Oncol; 2008 Sep 20; 25(6):509-21. PubMed ID: 18728970
    [Abstract] [Full Text] [Related]

  • 45. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study.
    Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I, Münzel K.
    Cancer; 2007 May 01; 109(9):1905-13. PubMed ID: 17351951
    [Abstract] [Full Text] [Related]

  • 46. Revisions in the prescribing information for Epoetin alfa: implications for nephrology nurses and patients on dialysis.
    Hayslip D.
    Nephrol Nurs J; 2008 May 01; 35(2):163-7. PubMed ID: 18472685
    [Abstract] [Full Text] [Related]

  • 47. Urinary neopterin, hemoglobin and peripheral blood cell counts in breast carcinoma patients treated with dose-dense chemotherapy.
    Melichar B, Urbánek L, Krcmová L, Kalábová H, Melicharová K, Malírová E, Hornychová H, Ryska A, Hyspler R, Solichová D.
    Anticancer Res; 2008 May 01; 28(4C):2389-96. PubMed ID: 18751424
    [Abstract] [Full Text] [Related]

  • 48. [Erythropoietic protein supportive treatment in small cell lung cancer].
    Tamási L, Müller V, Magyar P, Losonczy G.
    Magy Onkol; 2008 Mar 01; 52(1):43-6. PubMed ID: 18403296
    [Abstract] [Full Text] [Related]

  • 49. [Prediction of response to primary systemic chemotherapy involving weekly paclitaxel followed by FEC 100 for advanced breast cancer].
    Higaki K, Ohtani S, Kin R, Masumura K, Harano M, Urashima M, Kagemoto M, Takada S, Matsuura H.
    Gan To Kagaku Ryoho; 2008 Sep 01; 35(9):1513-7. PubMed ID: 18799903
    [Abstract] [Full Text] [Related]

  • 50. HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours.
    Weigang-Köhler K, Vetter A, Thyroff-Friesinger U.
    Onkologie; 2009 Apr 01; 32(4):168-74. PubMed ID: 19372711
    [Abstract] [Full Text] [Related]

  • 51. Transfusion requirement can be abolished by epoietin-a and autologous platelet predeposit in patients receiving high dose chemotherapy with stem cell support.
    Ponchio L, Zambelli A, De Stefano A, Robustelli Della Cuna FS, Perotti C, Pedrazzoli P.
    Haematologica; 2000 Feb 01; 85(2):219-20. PubMed ID: 10681739
    [No Abstract] [Full Text] [Related]

  • 52. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
    Juneja V, Keegan P, Gootenberg JE, Rothmann MD, Shen YL, Lee KY, Weiss KD, Pazdur R.
    Clin Cancer Res; 2008 Jun 01; 14(11):3242-7. PubMed ID: 18519748
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. [Efficacy of weekly epoetin Beta in the treatment of chemotherapy-induced anemia in solid tumors].
    Oudard S, Quoix E, Jenabian A, Bergougnoux L, Chouahnia K, Ferrero JM, Misset JL, Spaëth D.
    Therapie; 2009 Jun 01; 64(1):17-25. PubMed ID: 19463249
    [Abstract] [Full Text] [Related]

  • 57. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.
    Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A, Schneeweiss A, Kahlert S, von Koch F, Petry KU, Wallwiener D, Kreienberg R, Albert US, Lück HJ, Hinke A, Jänicke F, Konecny GE.
    J Clin Oncol; 2009 Jun 20; 27(18):2938-45. PubMed ID: 19364964
    [Abstract] [Full Text] [Related]

  • 58. Safety concerns about perisurgical epoetin treatment: should we add antiplatelet drugs to perisurgical epoetin alfa treatment?
    Basora M, Fita G, Matute P, Díaz-Ricart M.
    J Cardiothorac Vasc Anesth; 2007 Aug 20; 21(4):623-4. PubMed ID: 17678803
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.